Coronavirus

(NaturalHealth365) Analysis of data from 145 countries shows causal relationship between COVID jab rollout and increase in deaths and cases.

Background The incidence of SARS-CoV-2 infection, including among those who have received 2 doses of COVID-19 vaccines, has increased substantially since Omicron was first identified in the province of Ontario, Canada. Methods Applying the test-negative design to linked provincial data, we estimated vaccine effectiveness against infection (irrespective of symptoms or severity) caused by Omicron or Delta between November 22 and December 19, 2021. We included individuals who had received at least 2 COVID-19 vaccine doses (with at least 1 mRNA vaccine dose for the primary series) and used multivariable logistic regression to estimate the effectiveness of two or three doses by time since the latest dose. Results We included 3,442 Omicron-positive cases, 9,201 Delta-positive cases, and 471,545 test-negative controls. After 2 doses of COVID-19 vaccine, vaccine effectiveness against Delta infection declined steadily over time but recovered to 93% (95%CI, 92-94%) ≥7 days after receiving an mRNA vaccine for the third dose. In contrast, receipt of 2 doses of COVID-19 vaccines was not protective against Omicron. Vaccine effectiveness against Omicron was 37% (95%CI, 19-50%) ≥7 days after receiving an mRNA vaccine for the third dose. Conclusions Two doses of COVID-19 vaccines are unlikely to protect against infection by Omicron. A third dose provides some protection in the immediate term, but substantially less than against Delta. Our results may be confounded by behaviours that we were unable to account for in our analyses. Further research is needed to examine protection against severe outcomes. ### Competing Interest Statement K.W. is CEO of CANImmunize and serves on the data safety board for the Medicago COVID-19 vaccine trial. The other authors declare no conflicts of interest. ### Funding Statement This work was supported by the Canadian Immunization Research Network (CIRN) through a grant from the Public Health Agency of Canada and the Canadian Institutes of Health Research (CNF 151944). This project was also supported by funding from the Public Health Agency of Canada, through the Vaccine Surveillance Reference Group and the COVID-19 Immunity Task Force. This study was also supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH). J.C.K. is supported by Clinician-Scientist Award from the University of Toronto Department of Family and Community Medicine. P.C.A. is supported by a Mid-Career Investigator Award from the Heart and Stroke Foundation. This work was supported by Public Health Ontario. This study was also supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC). This study was supported by the Ontario Health Data Platform (OHDP), a Province of Ontario initiative to support Ontarios ongoing response to COVID-19 and its related impacts. The study sponsors did not participate in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication. Parts of this material are based on data and/or information compiled and provided by the Canadian Institute for Health Information (CIHI) and by Cancer Care Ontario (CCO). However, the analyses, conclusions, opinions and statements expressed herein are solely those of the authors, and do not reflect those of the funding or data sources; no endorsement by ICES, MOH, MLTC, OHDP, its partners, the Province of Ontario, CIHI or CCO is intended or should be inferred. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Section 45 of PHIPA authorizes ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system. Projects that use data collected by ICES under section 45 of PHIPA, and use no other data, are exempt from REB review. The use of the data in this project is authorized under section 45 and approved by ICES Privacy and Legal Office. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes The dataset from this study is held securely in coded form at ICES. While legal data sharing agreements between ICES and data providers (e.g., healthcare organizations and government) prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at www.ices.on.ca/DAS (email: das@ices.on.ca).

(NaturalHealth365) Lancet publishes letter questioning the narrative surrounding efficacy of COVID-19 injections. Are the jabs effective?

(NaturalHealth365) Canadian data show most hospitalized patients with COVID are fully vaxxed. Does the jab do more harm than good?

(NaturalHealth365) A recently published scientific review exposes the potentially catastrophic consequences of mRNA COVID jab.

(NaturalHealth365) In this interview, Israeli immunologist admits to multiple serious mistakes made during COVID-19 pandemic.

(NaturalHealth365) Fertility clinics have seen a huge surge in miscarriages and birth defects since the COVID shot rollout.

Use your smartphone to report any side effects after getting the COVID-19 vaccine, as well as reminders if you need a second dose.

In this brief communication we are showing original research results with early estimates from Danish nationwide databases of vaccine effectiveness (VE) against the novel SARS-CoV-2 Omicron variant (B.1.1.529) up to five months after a primary vaccination series with the BNT162b2 or mRNA-1273 vaccines. Our study provides evidence of protection against infection with the Omicron variant after completion of a primary vaccination series with the BNT162b2 or mRNA-1273 vaccines; in particular, we found a VE against the Omicron variant of 55.2% (95% confidence interval (CI): 23.5 to 73.7%) and 36.7% (95% CI: 69.9 to 76.4%) for the BNT162b2 and mRNA-1273 vaccines, respectively, in the first month after primary vaccination. However, the VE is significantly lower than that against Delta infection and declines rapidly over just a few months. The VE is re-established upon revaccination with the BNT162b2 vaccine (54.6%, 95% CI: 30.4 to 70.4%). ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study did not receive any funding ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: We used only administrative register data for the study. According to Danish law, ethics approval is exempt for such research, and the Danish Data Protection Agency, which is a dedicated ethics and legal oversight body, thus waives ethical approval for our study of administrative register data, when no individual contact of participants is necessary and only aggregate results are included as findings. The study is therefore fully compliant with all legal and ethical requirements and there are no further processes available regarding such studies. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes De-identified data are available for access to members of the scientific and medical community for non-commercial use only upon reasonable request to the authors

Public-health messaging from the beginning of this pandemic has had very little to say about immunity acquired following ...

Breakthrough infections are rising despite massive vaccination efforts. Is vaccine-induced immunity really better than natural immunity? Find out ...

These studies demonstrate what was and is already known: natural immunity for a SARS-type virus is robust, long-lasting, and broadly effective.

Part II: Targeting SARS-COV2

When it comes to the treatment of COVID-19, many Western nations have been hobbled by the politicization of ...

This article may be...

From the first reports coming out of Wuhan, Iran and later Italy, we knew that losing your sense ...

A cardiac MRI of college athletes who had COVID-19 is seven times more effective in detecting inflammation of ...

Dr. Pierre Kory is one of the leaders in the movement to provide early treatment for COVID infection. ...

Some viruses, such as measles, mumps and meningitis, can cause hearing difficulties, but what about SARS-CoV-2, the virus ...

Watch Episode 1: Vaccine Truth: Dispelling the Myths This first episode is packed with the TRUTH about the vaccine. We’ve gathered a group of top vaccine experts who have tried to get the information to you but, instead, have been censored and suppressed. PLUS, we have a special BRAND NEW BONUS EPISODE tonight, featuring Dr. Peter McCullough and Dr. Bryan Ardis. You’ll discover the alarming answers to questions about the vaccine that the “experts” don’t want you to know. What Dr. Peter McCullough, an internist and cardiologist in Dallas, Texas, had to say about the deadly spike protein will leave you speechless. Even U.S. federal agencies are trying to cover up the research coming out about the harmful vaxx (unsuccessfully, as Dr. McCullough reveals). He goes into detail about the hundreds and hundreds of cases all around the world of top athletes dropping dead on the playing field. This is extremely alarming to hear. And the rest of what he covers includes even more disturbing studies, revealing data about vaxxed victim’s autopsies and shocking news you won't hear anywhere else. Dr. Bryan Ardis dives into numerous disturbing facts that will leave your brain spinning. For example, why are male teenagers showing 20x the heart problems after the jab than the CDC expected (surely they told the FDA about this, right?) And you have to hear what he had to say about the shocking statement he found in the American Heart Association’s Circulation Journal regarding what they’ve seen happening to patients’ hearts after receiving the jab… Turns out it has been a MASSIVE coverup. Who would have guessed that? Dr. Ardis also discusses the one disease happening after the jab that’s worrying doctors all over the world (once diagnosed, 20% will die in 2 years, 50% will die in 5 years). You need to hear this directly from Dr. Ardis himself, for your own safety.

Her scientific conclusions about the COVID-19 pandemic and the origins of the CCP (Chinese Communist Party) virus are ...

In this interview with internationally renowned Dr. Shankara Chetty from South Africa, we discuss the Omicron variant, which is taking the world as a storm. Is this variant to be feared, or could it actually be a positive development in this pandemic, as mostly inducing mild disease, yet conferring post-covid natural immunity. These are among the timely and critically important aspects we discuss. Dr. Chetty is a Family General Medical Practitioner in South-Africa, with considerable experience with the outpatient treatment of COVID-19, having treated so far nearly 8,000 patients, in his outpatient practice, without any of them requiring hospitalization or even oxygen. Dr. Chetty holds a degree in medicine and surgery and also has advanced education in genetics, advanced biology, biochemistry and microbiology. More interviews: https://covexit.com/category/videos/

(NaturalHealth365) An unprecedented number of athletes have suffered cardiac issues in 2020. Could the COVID shot program be to blame?